Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:activities |
anti-inflammatory
|
| gptkbp:approves |
gptkb:legislation
gptkb:United_States |
| gptkbp:brand |
gptkb:Rhinocort
|
| gptkbp:category |
Category B
|
| gptkbp:class |
gptkb:physicist
|
| gptkbp:clinical_trial |
Phase III
seasonal allergies perennial allergies |
| gptkbp:community_service |
approved for children over 6 years
|
| gptkbp:contraindication |
hypersensitivity to budesonide
untreated fungal infections |
| gptkbp:dosage_form |
spray
32 mcg per spray 64 mcg per spray |
| gptkbp:duration |
as needed
|
| gptkbp:effective_date |
gptkb:1997
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
suspension
aqueous |
| gptkbp:frequency |
once daily
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rhinocort
|
| gptkbp:indication |
treatment of nasal symptoms
|
| gptkbp:ingredients |
gptkb:budesonide
|
| gptkbp:interacts_with |
CY P3 A4 inhibitors
|
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_effective_against |
improves quality of life
reduces nasal congestion |
| gptkbp:is_used_for |
nasal polyps
allergic rhinitis |
| gptkbp:lifespan |
2.5 hours
|
| gptkbp:manager |
intranasal
|
| gptkbp:manufacturer |
gptkb:temple
|
| gptkbp:marketed_as |
Rhinocort Aqua
Rhinocort Turbuhaler |
| gptkbp:metabolism |
liver
|
| gptkbp:packaging |
gptkb:beer
|
| gptkbp:pharmacokinetics |
rapid absorption
local effect on nasal mucosa |
| gptkbp:population |
adults and children
|
| gptkbp:provides_information_on |
recommended for moderate to severe symptoms
|
| gptkbp:safety_features |
generally well tolerated
not for use in children under 6 years |
| gptkbp:scholarships |
shake well before use
|
| gptkbp:side_effect |
fatigue
headache nausea cough nosebleeds dysgeusia throat irritation nasal irritation dryness of the nasal mucosa |
| gptkbp:storage |
room temperature
|
| gptkbp:bfsParent |
gptkb:budesonide
|
| gptkbp:bfsLayer |
5
|